Myriad Genetics Files 8-K on Financials

TL;DR

MYGN filed an 8-K today detailing financial results. Check it out.

AI Summary

Myriad Genetics, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report date and date of change both listed as November 7, 2024. The company is incorporated in Delaware and its principal executive offices are located in Salt Lake City, Utah.

Why It Matters

This 8-K filing provides an update on Myriad Genetics' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or material adverse events.

Key Players & Entities

• MYRIAD GENETICS INC (company) — Registrant
• November 7, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Salt Lake City, Utah (location) — Address of principal executive offices
• 801-584-3600 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar

Filing Documents

• mygn-20241107.htm (8-K) — 37KB
• mygn-ex991xearningsrelease.htm (EX-99.1) — 443KB
• 0000899923-24-000054.txt ( ) — 664KB
• mygn-20241107.xsd (EX-101.SCH) — 2KB
• mygn-20241107_def.xml (EX-101.DEF) — 14KB
• mygn-20241107_lab.xml (EX-101.LAB) — 25KB
• mygn-20241107_pre.xml (EX-101.PRE) — 15KB
• mygn-20241107_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

ITEM 2.02 Results of Operations and Financial Condition. On November 7, 2024, Myriad Genetics, Inc. ("Myriad" or the "Company") announced its financial results for the three months September 30, 2024. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K and Exhibit 99.1 contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the Company's updated fiscal year 2024 financial guidance, statements relating to the company's product pipeline and how these new products, once commercialized, have the potential to address a number of large market opportunities where the company believes it will have highly differentiated proprietary solutions, providing the company with opportunities to accelerate growth going forward, and statements about UnitedHealthcare's recent decision to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, such as GeneSight, under its commercial and individual exchange benefit plans, effective January 1, 2025, and the company's continued engagement with UnitedHealthcare to find a positive resolution for patients, including continued access to GeneSight. These "forward-looking statements" are management's present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: the risk that sales and profit margins of the Company's existing tests may decline; the risk that the Company may not be able to operate its business on a profitable basis; risks related to the Company's ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to changes in governmental or private insurers' coverage and reimbursement levels for the Company's tests or the Company's ability to obtain reimbursement for its new tests at comparable levels to its existing tests, including risks to the Company's business and financia

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Earnings release dated November 7, 2024 for the three months ended September 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K. In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: November 7, 2024 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR